Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 20, 2020World Journal of Surgical OncologyOpen Access

Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJiahang MoShanghai Hospital Development CenterXHXiao HuChinese Academy of Medical Sciences & Peking Union Medical CollegeLGLihu GuNingbo No. 2 Hospital

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mo et al. (2020) studied this question.

synapsesocial.com/papers/6a6119bf7133ea757584bdfbhttps://doi.org/10.1186/s12957-020-1792-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010 · 15,367 citations
  2. 2Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation2014 · 37 citations
  3. 3Transmembrane-4 L-six family member-1 (TM4SF1) promotes non-small cell lung cancer proliferation, invasion and chemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis2019 · 55 citations
  4. 4Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma2017 · 642 citations
  5. 5First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer2017 · 2,607 citations